New treatment approach for chronic neuropathic pain
Official title: Immunomodulatory Therapy for Neuropathic Pain
Funded at Apt Therapeutics, INC. · NIH-10684821 · Data updated 2026-11-12
This study is testing a new treatment using a low dose of a substance called interleukin-2 to help people with neuropathic pain feel better by boosting their body's natural defenses, and if you join, you could help us learn how well it works!
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Apt Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Naperville, UNITED STATES) |
| Project start | September 1, 2018 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $501,320 |
| NIH project number | 5R44NS106850-04 |
| Project ID | NIH-10684821 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from chronic neuropathic pain who have not found relief from existing treatments.
✕Less likely to help
Patients with acute pain conditions or those who do not have neuropathic pain may not benefit from this research.
What this research studies
This research investigates a novel immunomodulatory therapy aimed at treating neuropathic pain, which affects millions of Americans. The approach focuses on using low-dose interleukin-2 (IL-2) to enhance the body's regulatory T cells, which may help reduce inflammation and improve pain management. By targeting the underlying mechanisms of neuropathic pain rather than just alleviating symptoms, this therapy seeks to provide a more effective and safer alternative to current opioid treatments. Patients participating in this research may receive this innovative therapy and contribute to understanding its effectiveness.
Why it matters
Potential benefit: If successful, this research could provide a safer, non-opioid treatment option for patients suffering from chronic neuropathic pain.
How similar studies have gone: Previous studies have shown promising results with similar immunomodulatory approaches in treating autoimmune diseases, suggesting potential for success in neuropathic pain management.
Where this research is happening
-
Apt Therapeutics, INC.
Naperville, United States Active
Researchers
- Principal investigator: Chen, Ridong — Apt Therapeutics, INC.
- Study coordinator: Chen, Ridong
Related research
Other NIH-funded projects on the same topics.
-
Peripheral nerve stimulation for chronic neuropathic pain in a new mechanistic trial
A study at Stanford tests whether a painless-sounding electrical nerve treatment helps people with long-standing neuropathic pain when added to standard care.
-
Keratinocytes and nerve pain in chemotherapy patients
A study tests a new approach to reduce painful nerve damage from chemotherapy by targeting skin cells called keratinocytes.
-
High-frequency brain stimulation for trigeminal neuropathic pain
A large, multi-site trial tests a non-invasive brain stimulation method to relieve chronic facial nerve pain for adults who have not found relief from other treatments.
-
Programmable lithium-delivery devices for pain relief without motor loss
A new bioelectronic system uses a safe lithium source and AI-powered control to deliver targeted pain relief for neuropathic pain, aiming to spare motor function.
-
Glial-nerve conversations in neuropathic pain and diabetes
This grant looks at how supportive brain and nerve cells communicate with pain-sensing neurons to understand and reduce chronic nerve pain in people.
-
Parmodulins with Low Abuse Potential for Neuropathic Pain
A new class of pain medicines called parmodulins is being studied to help people with nerve-pain pain without high abuse risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.